Dr. Nigel Scott is Celixir’s Global Head of Regulatory Affairs.
Dr. Scott holds a MB, BChir from the University of Cambridge, a Masters in Genetics and PhD in Protein Biochemistry from the University of London.
Prior to entering the industry, Dr Scott was a pathologist, with a special interest in transfusion medicine and particularly bone marrow transplantation.
Since joining the industry, Dr. Scott has held increasingly senior regulatory affairs positions in Bristol Myers Squibb, AstraZeneca, Fulcrum Pharma and most recently Daiichi Sankyo.
At Daiichi Sankyo, Nigel was the Senior Director of Regulatory Affairs for Europe with responsibility for all non-oncology products and all European interactions with EU Competent Authorities.
Dr. Scott has contributed to many clinical trials and either led or supported a number of marketing authorisations for leading medicines through National or Centralised Procedures.
In his last role, Dr. Scott was responsible for the European Registration of Lixiana®(edoxaban) via the Centralised Procedure in Switzerland.